Interestingly, stimulation of nitric oxide signalling with vericiguat reduced the combined endpoint of CV death and/or HF admission in patients with HF with reduced ejection fraction.27 NLRP3 inflammasome inhibition is also one of the postulated mechanisms by which sodium-glucose cotransporter-2 inhibitors exert beneficial CV effects.28 Enhanced IFN-γ activity might partially exert some of its protective effects in a similar manner. The gene discussed is NLRP3; the disease is hydrops fetalis.